HARMONi-10: A phase 3 open-label study of ivonescimab versus durvalumab as consolidation therapy in unresectable stage III non-small cell lung cancer without progression after definitive platinum-based concurrent chemoradiotherapy
Sponsor: Summit Therapeutics Inc.
Phase: 3
Disease: Non-small cell lung cancer
EU trial number: 2026-526300-67-00
Population: Adults aged at least 18 with histologically or cytologically documented unresectable locally advanced stage III NSCLC, ECOG performance status 0–1, known PD-L1 status and no RECIST-defined disease progression after definitive concurrent platinum-based chemoradiotherapy.
Register Investigator Interest
Interested in offering this trial to suitable patients?